Cargando…

The PET-derived tumor-to-blood standard uptake ratio (SUR) is superior to tumor SUV as a surrogate parameter of the metabolic rate of FDG

BACKGROUND: The standard uptake value (SUV) approach in oncological positron emission tomography has known shortcomings, all of which affect the reliability of the SUV as a surrogate of the targeted quantity, the metabolic rate of [(18)F]fluorodeoxyglucose (FDG), K(m). Among the shortcomings are tim...

Descripción completa

Detalles Bibliográficos
Autores principales: van den Hoff, Jörg, Oehme, Liane, Schramm, Georg, Maus, Jens, Lougovski, Alexandr, Petr, Jan, Beuthien-Baumann, Bettina, Hofheinz, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4175513/
https://www.ncbi.nlm.nih.gov/pubmed/24267032
http://dx.doi.org/10.1186/2191-219X-3-77
_version_ 1782336497355063296
author van den Hoff, Jörg
Oehme, Liane
Schramm, Georg
Maus, Jens
Lougovski, Alexandr
Petr, Jan
Beuthien-Baumann, Bettina
Hofheinz, Frank
author_facet van den Hoff, Jörg
Oehme, Liane
Schramm, Georg
Maus, Jens
Lougovski, Alexandr
Petr, Jan
Beuthien-Baumann, Bettina
Hofheinz, Frank
author_sort van den Hoff, Jörg
collection PubMed
description BACKGROUND: The standard uptake value (SUV) approach in oncological positron emission tomography has known shortcomings, all of which affect the reliability of the SUV as a surrogate of the targeted quantity, the metabolic rate of [(18)F]fluorodeoxyglucose (FDG), K(m). Among the shortcomings are time dependence, susceptibility to errors in scanner and dose calibration, insufficient correlation between systemic distribution volume and body weight, and, consequentially, residual inter-study variability of the arterial input function (AIF) despite SUV normalization. Especially the latter turns out to be a crucial factor adversely affecting the correlation between SUV and K(m) and causing inter-study variations of tumor SUVs that do not reflect actual changes of the metabolic uptake rate. In this work, we propose to replace tumor SUV by the tumor-to-blood standard uptake ratio (SUR) in order to distinctly improve the linear correlation with K(m). METHODS: Assuming irreversible FDG kinetics, SUR can be expected to exhibit a much better linear correlation to K(m) than SUV. The theoretical derivation for this prediction is given and evaluated in a group of nine patients with liver metastases of colorectal cancer for which 15 fully dynamic investigations were available and K(m) could thus be derived from conventional Patlak analysis. RESULTS: For any fixed time point T at sufficiently late times post injection, the Patlak equation predicts a linear correlation between SUR and K(m) under the following assumptions: (1) approximate shape invariance (but arbitrary scale) of the AIF across scans/patients and (2) low variability of the apparent distribution volume V(r) (the intercept of the Patlak Plot). This prediction - and validity of the underlying assumptions - has been verified in the investigated patient group. Replacing tumor SUVs by SURs does improve the linear correlation of the respective parameter with K(m) from r = 0.61 to r = 0.98. CONCLUSIONS: SUR is an easily measurable parameter that is highly correlated to K(m). In this respect, it is clearly superior to SUV. Therefore, SUR should be seriously considered as a drop-in replacement for SUV-based approaches.
format Online
Article
Text
id pubmed-4175513
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Springer
record_format MEDLINE/PubMed
spelling pubmed-41755132014-09-30 The PET-derived tumor-to-blood standard uptake ratio (SUR) is superior to tumor SUV as a surrogate parameter of the metabolic rate of FDG van den Hoff, Jörg Oehme, Liane Schramm, Georg Maus, Jens Lougovski, Alexandr Petr, Jan Beuthien-Baumann, Bettina Hofheinz, Frank EJNMMI Res Original Research BACKGROUND: The standard uptake value (SUV) approach in oncological positron emission tomography has known shortcomings, all of which affect the reliability of the SUV as a surrogate of the targeted quantity, the metabolic rate of [(18)F]fluorodeoxyglucose (FDG), K(m). Among the shortcomings are time dependence, susceptibility to errors in scanner and dose calibration, insufficient correlation between systemic distribution volume and body weight, and, consequentially, residual inter-study variability of the arterial input function (AIF) despite SUV normalization. Especially the latter turns out to be a crucial factor adversely affecting the correlation between SUV and K(m) and causing inter-study variations of tumor SUVs that do not reflect actual changes of the metabolic uptake rate. In this work, we propose to replace tumor SUV by the tumor-to-blood standard uptake ratio (SUR) in order to distinctly improve the linear correlation with K(m). METHODS: Assuming irreversible FDG kinetics, SUR can be expected to exhibit a much better linear correlation to K(m) than SUV. The theoretical derivation for this prediction is given and evaluated in a group of nine patients with liver metastases of colorectal cancer for which 15 fully dynamic investigations were available and K(m) could thus be derived from conventional Patlak analysis. RESULTS: For any fixed time point T at sufficiently late times post injection, the Patlak equation predicts a linear correlation between SUR and K(m) under the following assumptions: (1) approximate shape invariance (but arbitrary scale) of the AIF across scans/patients and (2) low variability of the apparent distribution volume V(r) (the intercept of the Patlak Plot). This prediction - and validity of the underlying assumptions - has been verified in the investigated patient group. Replacing tumor SUVs by SURs does improve the linear correlation of the respective parameter with K(m) from r = 0.61 to r = 0.98. CONCLUSIONS: SUR is an easily measurable parameter that is highly correlated to K(m). In this respect, it is clearly superior to SUV. Therefore, SUR should be seriously considered as a drop-in replacement for SUV-based approaches. Springer 2013-11-23 /pmc/articles/PMC4175513/ /pubmed/24267032 http://dx.doi.org/10.1186/2191-219X-3-77 Text en Copyright © 2013 van den Hoff et al.; licensee Springer. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research
van den Hoff, Jörg
Oehme, Liane
Schramm, Georg
Maus, Jens
Lougovski, Alexandr
Petr, Jan
Beuthien-Baumann, Bettina
Hofheinz, Frank
The PET-derived tumor-to-blood standard uptake ratio (SUR) is superior to tumor SUV as a surrogate parameter of the metabolic rate of FDG
title The PET-derived tumor-to-blood standard uptake ratio (SUR) is superior to tumor SUV as a surrogate parameter of the metabolic rate of FDG
title_full The PET-derived tumor-to-blood standard uptake ratio (SUR) is superior to tumor SUV as a surrogate parameter of the metabolic rate of FDG
title_fullStr The PET-derived tumor-to-blood standard uptake ratio (SUR) is superior to tumor SUV as a surrogate parameter of the metabolic rate of FDG
title_full_unstemmed The PET-derived tumor-to-blood standard uptake ratio (SUR) is superior to tumor SUV as a surrogate parameter of the metabolic rate of FDG
title_short The PET-derived tumor-to-blood standard uptake ratio (SUR) is superior to tumor SUV as a surrogate parameter of the metabolic rate of FDG
title_sort pet-derived tumor-to-blood standard uptake ratio (sur) is superior to tumor suv as a surrogate parameter of the metabolic rate of fdg
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4175513/
https://www.ncbi.nlm.nih.gov/pubmed/24267032
http://dx.doi.org/10.1186/2191-219X-3-77
work_keys_str_mv AT vandenhoffjorg thepetderivedtumortobloodstandarduptakeratiosurissuperiortotumorsuvasasurrogateparameterofthemetabolicrateoffdg
AT oehmeliane thepetderivedtumortobloodstandarduptakeratiosurissuperiortotumorsuvasasurrogateparameterofthemetabolicrateoffdg
AT schrammgeorg thepetderivedtumortobloodstandarduptakeratiosurissuperiortotumorsuvasasurrogateparameterofthemetabolicrateoffdg
AT mausjens thepetderivedtumortobloodstandarduptakeratiosurissuperiortotumorsuvasasurrogateparameterofthemetabolicrateoffdg
AT lougovskialexandr thepetderivedtumortobloodstandarduptakeratiosurissuperiortotumorsuvasasurrogateparameterofthemetabolicrateoffdg
AT petrjan thepetderivedtumortobloodstandarduptakeratiosurissuperiortotumorsuvasasurrogateparameterofthemetabolicrateoffdg
AT beuthienbaumannbettina thepetderivedtumortobloodstandarduptakeratiosurissuperiortotumorsuvasasurrogateparameterofthemetabolicrateoffdg
AT hofheinzfrank thepetderivedtumortobloodstandarduptakeratiosurissuperiortotumorsuvasasurrogateparameterofthemetabolicrateoffdg
AT vandenhoffjorg petderivedtumortobloodstandarduptakeratiosurissuperiortotumorsuvasasurrogateparameterofthemetabolicrateoffdg
AT oehmeliane petderivedtumortobloodstandarduptakeratiosurissuperiortotumorsuvasasurrogateparameterofthemetabolicrateoffdg
AT schrammgeorg petderivedtumortobloodstandarduptakeratiosurissuperiortotumorsuvasasurrogateparameterofthemetabolicrateoffdg
AT mausjens petderivedtumortobloodstandarduptakeratiosurissuperiortotumorsuvasasurrogateparameterofthemetabolicrateoffdg
AT lougovskialexandr petderivedtumortobloodstandarduptakeratiosurissuperiortotumorsuvasasurrogateparameterofthemetabolicrateoffdg
AT petrjan petderivedtumortobloodstandarduptakeratiosurissuperiortotumorsuvasasurrogateparameterofthemetabolicrateoffdg
AT beuthienbaumannbettina petderivedtumortobloodstandarduptakeratiosurissuperiortotumorsuvasasurrogateparameterofthemetabolicrateoffdg
AT hofheinzfrank petderivedtumortobloodstandarduptakeratiosurissuperiortotumorsuvasasurrogateparameterofthemetabolicrateoffdg